NLS Pharmaceutics secures patent in Japan for Mazindol ER

NLS Pharmaceutics (NLSP) announced that its Japanese patent application No. 2020-513594 has been granted. The patent covers the use of Mazindol ER for the treatment of heroin dependence, providing a new therapeutic strategy for opioid use disorder. “The development of mazindol as a treatment for substance use disorder could represent a significant breakthrough, offering new hope for patients battling addiction. It is crucial we align our strategy with the evolving landscape of pharmaceutical innovation in this area.” said Alex Zwyer, CEO. “This application highlights the continued commitment from NLS to pioneer therapeutic approaches to address significant unmet medical needs.”